Derek G. Power

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo et al. · The Lancet · 2023 · 891 citations · Full text

Urology, Surgical Oncology, Gastrointestinal Oncology +5

Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma

Mario Sznol, Pier Francesco Ferrucci, David Hogg et al. · Journal of Clinical Oncology · 2017 · 293 citations

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl D. Lewis, Lev Demidov et al. · The Lancet Oncology · 2018 · 210 citations · Full text

Medicine, Melanoma, Immunology +10

Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer

Louise E. Daly, Éadaoin B. Ní Bhuachalla, Derek G. Power et al. · Journal of Cachexia Sarcopenia and Muscle · 2018 · 192 citations · Full text

The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma

Louise E. Daly, Derek G. Power, Aine O’Reilly et al. · British Journal of Cancer · 2017 · 172 citations · Full text